A novel hepatic-targeting system for therapeutic cytokines that delivers to the hepatic asialoglycoprotein receptor, but avoids receptor-mediated endocytosis

Pharmaceutical Research

Volumn 19, Issue 11, 2002, Pages 1736-1744

  Sato, H ^a   Kato, Y ^a,b   Hayashi, E ^a   Tabata, T ^a   Suzuki, M ^a   Takahara, Y ^a   Sugiyama, Y ^a,b  

^a AJINOMOTO CO INC   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Galactose; Hepatic tumor; Interleukin 2; Low affinity ligand; Physiologically based pharmacokinetic model; Transglutaminase

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; CELL SURFACE RECEPTOR; CYTOKINE; GALACTOSE; INTERLEUKIN 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL SURFACE; CONTROLLED STUDY; DISSOCIATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG UPTAKE; ENDOCYTOSIS; EXTRACELLULAR SPACE; INTERNALIZATION; LIGAND BINDING; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ASIALOGLYCOPROTEIN RECEPTOR; CELLS, CULTURED; CYTOKINES; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; HEPATOCYTES; MALE; MICE; MICE, INBRED C57BL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036846909     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020773800358     Document Type: Article

References (28)

1. G. Ashwell and J. Harford. Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 51:531-554 (1982).
2. M. Spiess. The asialoglycoprotein receptor: A model for endocytic transport receptors. Biochemistry 29:10009-10018 (1990).
3. Y. C. Lee, R. R. Townsend, M. R. Hardy, J. Lonngren, J. Arnarp, M. Haraldsson, and H. Lonn. Binding of synthetic oligosaccharides to the hepatic Gal/(GalNAc) lectin. Dependence on fine structural features. J. Biol. Chem. 258:199-202 (1983).
4. R. T. Lee, P. Lin, and Y. C. Lee. New synthetic cluster ligands for galactose/N-acetylgalactosamine-specific lectin of mammalian liver. Biochemistry 23:4255-4261 (1984).
5. K. Kasama, J. Utsumi, E. Matsuo-Ogawa, T. Nagahata, Y. Kagawa, S. Yamazaki, and Y. Satoh. Pharmacokinetics and biologic activities of human native and asialointerferon-beta s. J. Interferon Cytokine Res. 15:407-415 (1995).
6. Y. Yabe, M. Nishikawa, A. Tamada, Y. Takakura, and M. Hashida. Targeted delivery and improved therapeutic potential of catalase by chemical modification: Combination with superoxide dismutase derivatives. J. Pharmacol. Exp. Ther. 289:1176-1184 (1999).
7. H. Sato, E. Hayashi, N. Yamada, M. Yatagai, and Y. Takahara. Further studies on the site-specific protein modification by microbial transglutaminase. Bioconjug. Chem. 12:701-710 (2001).
8. T. Tsuji, R. Nakagawa, N. Sugimoto, and K. Fukuhara. Characterization of disulfide bonds in recombinant proteins: Reduced human interleukin 2 in inclusion bodies and its oxidative refolding. Biochemistry 246:3129-3134 (1987).
9. M. D. Bider, R. Cescato, P. Jeno, and M. Spiess. High-affinity ligand binding to subunit H1 of the asialoglycoprotein receptor in the absence of subunit H2. Eur. J. Biochem. 230:207-212 (1995).
10. H. Sato, Y. Takahara, E. Hayashi, M. Yatagai, M. Suzuki, T. Tabata, and C. Ejima. Modified physiologically active protein and pharmaceutical composition containing the same. P.C.T. JP97/03435.
11. S. Gillis, M. M. Ferm, W. Ou, and K. A. Smith. T cell growth factor: Parameters of production and a quantitative microassay for activity. J. Immunol. 120:2027-2032 (1978).
12. 131I-labeled human growth hormone of high specific activity. Biochem. J. 89:114-123 (1963).
13. J. Hamuro, T. Kikuchi, F. Takatsuki, and M. Suzuki. Cancer cell progression and chemoimmunotherapy - Dual effects in the induction of resistance to therapy. Br. J. Cancer 73:465-471 (1996).
14. M. Suzuki, T. Kikuchi, F. Takatsuki, and J. Hamuro. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells. Cancer Immunol. Immunother. 38:1-8 (1994).
15. P. O. Seglen. Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J. Toxicol. Environ. Health 5:551-560 (1979).
16. E. A. Biessen, D. M. Beuting, H. C. Roelen, G. A. van de Marel, J. H. van Boom, and T. J. van Berkel. Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor. J. Med. Chem. 38:1538-1546 (1995).
17. T. Kuwabara, S. Kobayashi, and Y. Sugiyama. Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells. Am. J. Physiol. 271:E73-84 (1996).
18. A. Hisaka, and Y. Sugiyama. Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method. J. Pharmacokinet. Biopharm. 26:495-519 (1998).
19. G. Ju, L. Collins, K. L. Kaffka, W. H. Tsien, R. Chizzonite, R. Crowl, R. Bhatt, and P. L. Kilian. Structure-function analysis of human interleukin-2. Identification of amino acid residues required for biological activity. J. Biol. Chem. 262:5723-5731 (1987).
20. R. R. Townsend, M. R. Hardy, T. C. Wong, and Y. C. Lee. Binding of N-linked bovine fetuin glycopeptides to isolated rabbit hepatocytes: Gal/GalNAc hepatic lectin discrimination between Gal beta(1,4)GlcNAc and Gal beta(1,3)GlcNAc in a triantennary structure. Biochemistry 25:5716-5725 (1986).
21. H. S. Sabzevari, S. D. Gllies, B. M. Mueller, and J. D. Pancook. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. USA 91:9626-9630 (1994).
22. H. Abdih, C.J. Kelly, D. Bouchier-Hayes, M. Barry, and S. Kearns. Taurine prevents interleukin-2-induced acute lung injury in rats. Eur. Surg. Res. 32:347-352 (2000).
23. H. Mann, J. H. Ward, and W. E. Samlowski. Vascular leak syndrome associated with interleukin-2: Chest radiographic manifestations. Radiology 176:191-194 (1990).
24. T. J. C. van Berkel, C. J. Dekker, J. K. Kruijt, and H. G. van Eijk. The interaction in vivo of transferrin and asialotransferrin with liver cells. Biochem. J. 243:715-722 (1987).
25. Y. Takakura, S. Masuda, H. Tokuda, M. Nishikawa, and M. Hashida. Targeted delivery of superoxide dismutase to macrophages via mannose receptor-mediated mechanism. Biochem. Pharmacol. 47:853-858 (1994).
26. R. J. Lee and P. S. Low. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:3198-3204 (1994).
27. S. P. Vyas, A. Singh, and V. Sihorkar. Ligand-receptor-mediated drug delivery: An emerging paradigm in cellular drug targeting. Crit. Rev. Ther. Drug Carrier Syst. 18:1-76 (2001).
28. R. L. Dedrick, D. D. Forrester, J. N. Cannon, S. M. el-Dareer, L. B. Mellett. Pharmacokinetics of 1-b-D-arbino-furanosylcytocine (Ara-C) deamination in several species. Biochem. Pharmacol. 22:2405-2417 (1973).